RIPARIAN PHARMACEUTICALS INC
BOSTON, MA · CIK 0001755048 · Biotech · Private
Small molecule KLF2 pathway activators for treatment of hypertension and endothelial dysfunction
riparianpharma.com →- Grants
- $5.9M
- 7 awards
- Sector median: 1
- Raised
- $500K
- 1 Form D · Oct 2018
- 96 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 0 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis | $857,294 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis | $2,804,643 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis | $19,598 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis | $1,229,878 | |
| Federal grant | Department of Health and Human Services · Phase II · Therapeutic Reversal of Endothelial Dysfunction in Atherogenesis | $697,873 | |
| Private capital raised | Form D · SEC | $500,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Pharmacological induction of KLF2 and reversal of endothelial dysfunction for the treatment of hypertension | $310,743 | |
| Federal grant | Department of Health and Human Services · Phase I · Pharmacological induction of KLF2 and reversal of endothelial dysfunction for the treatment of hypertension | $6,500 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1912 | GRO BIOSCIENCES INC | — | — |
| 1913 | SET THERAPEUTICS INC | — | — |
| 1914 | Cogent Biosciences | — | — |
| 1915 | RIPARIAN PHARMACEUTICALS INC | — | $500K |
| 1916 | Origin Protocol, Inc. | — | $38M |
| 1917 | NGM Bio Holdings, Inc. | — | $73M |
| 1918 | CELESTIAL THERAPEUTICS INC | — | $125K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- William AdamsDirector · Executive Officer
- Michael Serrano-WuDirector
Patents
- Inducers Of KLF2 And Methods Of Use Thereofapplication
- Inducers Of KLF2 And Methods Of Use Thereofapplication
- Inducers Of KLF2 And Methods Of Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.